|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2003-3-7
|
|
pubmed:abstractText |
A novel immunological approach to colon cancer therapy is the antibody targeting of the fibroblast activation protein (FAP), which is highly expressed by stroma cells of this tumour. Unconjugated sibrotuzumab (BIBH 1), which is a humanised version of the murine anti-FAP mAb F19, was investigated for its anti-tumour activity, safety and pharmacokinetics.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Gelatinases,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Serine Endopeptidases,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/fibroblast activation protein alpha
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0378-584X
|
|
pubmed:author |
pubmed-author:AmelsbergAA,
pubmed-author:HartmannFF,
pubmed-author:HartungGG,
pubmed-author:HofheinzR-DRD,
pubmed-author:JägerDD,
pubmed-author:KENTA BAB,
pubmed-author:KuthanHH,
pubmed-author:RennerCC,
pubmed-author:StehleGG,
pubmed-author:TanswellPP,
pubmed-author:al-BatranS-ESE
|
|
pubmed:copyrightInfo |
Copyright 2003 S. Karger GmbH, Freiburg
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
44-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12624517-Aged,
pubmed-meshheading:12624517-Antibodies, Monoclonal,
pubmed-meshheading:12624517-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:12624517-Antigens, Neoplasm,
pubmed-meshheading:12624517-Colorectal Neoplasms,
pubmed-meshheading:12624517-Disease Progression,
pubmed-meshheading:12624517-Dose-Response Relationship, Drug,
pubmed-meshheading:12624517-Drug Administration Schedule,
pubmed-meshheading:12624517-Female,
pubmed-meshheading:12624517-Follow-Up Studies,
pubmed-meshheading:12624517-Gelatinases,
pubmed-meshheading:12624517-Humans,
pubmed-meshheading:12624517-Infusions, Intravenous,
pubmed-meshheading:12624517-Liver Neoplasms,
pubmed-meshheading:12624517-Lung Neoplasms,
pubmed-meshheading:12624517-Male,
pubmed-meshheading:12624517-Membrane Proteins,
pubmed-meshheading:12624517-Middle Aged,
pubmed-meshheading:12624517-Palliative Care,
pubmed-meshheading:12624517-Serine Endopeptidases,
pubmed-meshheading:12624517-Treatment Outcome,
pubmed-meshheading:12624517-Tumor Markers, Biological
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer.
|
|
pubmed:affiliation |
Onkologisches Zentrum, III. Medizinische Klinik, Universitätsklinikum Mannheim, Germany. ralf.hofheinz@med3.ma.uni-heidelberg.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Evaluation Studies,
Clinical Trial, Phase II
|
